Radiobiological aspects of brachytherapy in the era of 3-dimensional imaging

Gynecologic Radiation Therapy: Novel Approaches to Image-Guidance and Management

Volumn , Issue , 2011, Pages 131-142

  Stewart, Alexandra J ^a   Bentzen, Soren M ^b  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869135891     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-68958-4_11     Document Type: Chapter

References (68)

1. Stitt JA, Fowler JF, Thomadsen B.R., et al. High dose rate intracavitary brachytherapy for carcinoma of the cervix: the Madison system: I. Clinical and radiobiological consideration. Int J Radiat Oncol Biol Phys. 1992; 24: 335-48.
2. Brenner DJ, Huang Y, Hall EJ. Fractionated high dose rate versus low dose rate regimens for intracavitary brachytherapy of the cervix: equivalent regimens for combined brachytherapy and external irradiation. Int J Radiat Oncol Biol Phys. 1991; 21: 1415-23.
3. Eifel PJ. High-dose-rate brachytherapy for carcinoma of the cervix: high tech or high risk? Int J Radiat Oncol Biol Phys. 1992; 24: 383-6.
4. ICRU 38. Dose and volume specifications for reporting intracavitary therapy in gynecology. Bethesda: International Commission on Radiation Units and Measurements; 1985. pp. 1-23.
5. Dale RG, Fowler JF. Radiation repair mechanisms. In: Dale RG, Jones B, editors. Radiobiological modelling in radiation oncology. London: British Institute of Radiology; 2007.
6. Fu KK, Ling CC, Nath R, et al. Radiobiology of brachytherapy. In: Interstitial brachytherapy: Physical, Biological and Clinical Considerations (Interstitial Collaborative Working Group). Eds Anderson LL and the Interstitial Collaborative Working Group. New York: Raven Press Ltd; 1990.
7. Dale RG, Jones B. The clinical radiobiology of brachytherapy. Br J Radiol. 1998; 71: 465-83.
8. Mason KA, Thames HD, Ochran T.G., et al. Comparison of continuous and pulsed low dose rate brachytherapy: biological equivalence in vivo. Int J Radiat Oncol Biol Phys. 1994; 28: 667-71.
9. Armour EP, White JR, Armin A, et al. Pulsed low dose rate brachytherapy in a rat model: dependence of late rectal injury on radiation pulse size. Int J Radiat Oncol Biol Phys. 1997; 38: 825-34.
10. Visser AG, van den Aardweg GJ, Levendag PC. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments. Int J Radiat Oncol Biol Phys. 1996; 34: 497-505.
11. Fowler JF, van Limbergen EFM. Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues. Int J Radiat Oncol Biol Phys. 1997; 37: 877-83.
12. Dale RG. The application of the linear quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985; 58: 515-28.
13. Joiner MC, van der Kogel AJ. The linear quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG, editor. Basic clinical radiobiology. 3rd ed. London: Hodder Arnold; 1997. p. 106-22.
14. Bentzen SM, Joiner MC. The linear quadratic approach in clinical practice. In: Joiner MC, van der Kogel A, editors. Basic clinical radiobiology. 4th ed. London: Hodder Arnold; 2009. p. 120-34.
15. Pop LA, van den Broek JF, Visser AG, et al. Constraints in the use of repair half times and mathematical modelling for the clinical application of HDR and PDR treatment schedules as an alternative for LDR brachytherapy. Radiother Oncol. 1996; 38: 153-62.
16. Bentzen SM, Saunders MI, Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol. 1999; 53: 219-26.
17. Steel G. Basic Clinical Radiobiology, Vol. 1. 3rd ed. London: Arnold; 2002.
18. Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006; 78: 67-77.
19. Noda SE, Ohno T, Kato S., et al. Late rectal complications evaluated by computed tomography-based dose calculations in patients with cervical carcinoma undergoing high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2007; 69: 118-24.
20. Clark BG, Souhami L, Roman T.N., et al. The prediction of late rectal complications in patients treated with high dose rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1997; 38: 989-93.
21. Yoshimura R, Hayashi K, Ayukawa F., et al. Radiotherapy doses at special reference points correlate with the outcome of cervical cancer therapy. Brachytherapy. 2008; 7: 260-6.
22. Guerrero M, Li XA. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol. 2004; 49: 4825-35.
23. Fowler JF. Is repair of DNA strand break damage from ionizing radiation second-order rather than frst-order? A simpler explanation of apparently multiexponential repair. Radiat Res. 1999; 152: 124-36.
24. Millar WT, Canney PA. Derivation and application of equations describing the effects of fractionated protracted irradiation, based on multiple and incomplete repair processes. Part 1L: Derivation of equations. Int J Radiobiol. 1993; 64: 275-91.
25. Orton C. High dose rate brachytherapy may be radiobiologically superior to low dose rate due to slow repair of late responding normal tissue cells. Int J Radiat Oncol Biol Phys. 2001; 49: 183-9.
26. Denham JW, Hamilton CS, Simpson S.A., O'Brien MY, Ostwald PM, Kron T, et al. Acute reaction parameters for human oropharyngeal mucosa. Radiother Oncol. 1995; 35: 129-37.
27. Roberts SA, Hendry JH, Swindell R, et al. Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial. Radiother Oncol. 2004; 70: 63-74.
28. Bentzen SM, Ruifrok AC, Thames HD. Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. Radiother Oncol. 1996; 38: 89-101.
29. Bentzen SM. Design of clinical trials in radiation oncology: saving lives not grays. In: JB DR, editor. Radiobiological modelling in radiation oncology. London: British Institute of Radiology; 2007. p. 196-211.
30. Jones B, Dale RG. The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. Br J Radiol. 2005; 78: 939-44.
31. Jones B, Dale RG, Gaya AM. Linear quadratic modelling of increased late normal-tissue effects in special clinical situations. Int J Radiat Oncol Biol Phys. 2006; 64: 948-53.
32. Meredith WJ. Radium dosage: the Manchester system. Baltimore: Williams & Wilkins; 1949.
33. Hoskin PJ, Rembowska A. Dosimetry rules for brachytherapy using high dose rate remote afterloading implants. Clin Onc. 1998; 10: 226-30.
34. Mai J, Erickson B, Rownd J., et al. Comparison of four different dose specification methods for high dose rate intracavitary radiation for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2001; 51: 1131-41.
35. Lee SW, Suh CO, Chung E.J., et al. Dose optimization of fractionated external radiation and high dose rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 2002; 52: 1338-44.
36. Foroudi F, Bull CA, Gebski V. Radiation therapy for cervix carcinoma: benefts of individualized dosimetry. Clin Onc. 2002; 14: 43-9.
37. Pierquin B, Dutreix A, Paine C.H., et al. The Paris system in interstitial radiation therapy. Acta Radiol Oncol Radiat Phys Biol. 1978; 17: 33-48.
38. Teshima T, Inoue T, Ikeda H., et al. High dose rate and low dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer. 1993; 72: 2409-14.
39. Patel FD, Sharma SC, Negi P.S., et al. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys. 1993; 28: 335-41.
40. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K., et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys. 2004; 59: 1424-31.
41. Hareyama M, Sakata K, Oouchi A., et al. High dose rate versus low dose rate intracavitary therapy for carcinoma of the uterine cervix. Cancer. 2002; 94: 117-24.
42. Stewart AJ, Viswanathan AN. Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer. Cancer. 2006; 107: 908-15.
43. Shrivastava S, Dinshaw K, Mahanshetty U., et al. Comparing low-dose-rate and high-dose-rate intracavitary brachytherapy in carcinoma cervix: results from a randomized controlled study. Int J Radiat Oncol Biol Phys. 2006; 66:S42.
44. Viani GA, Manta GB, Stefano E.J., et al. Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy - a meta-analysis of clinical trials. J Exp Clin Cancer Res. 2009; 28: 47.
45. Stewart AJ, Jones B. Radiobiological concepts for brachytherapy. In: Devlin P, editor. Brachytherapy: applications and techniques. 1st ed. Baltimore: Lippincott, Williams & Wilkins; 2006.
46. Ling CC, Spiro IJ, Mitchell J, et al. The variation of OER with dose rate. Int J Radiat Oncol Biol Phys. 1985; 11: 1367-73.
47. Dale RG. The use of small fraction numbers in high dose-rate gynaecological afterloading: some radiobiological considerations. Br J Radiol. 1990; 63: 290-4.
48. Dale RG, Coles IP, Deehan C, et al. Calculation of integrated biological response in brachyther-apy. Int J Radiat Oncol Biol Phys. 1997; 38: 633-42.
49. Haie-Meder C., Kramar A, Lambin P., et al. Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1994; 29: 953-60.
50. Lambin P, Gerbaulet A, Kramar A., et al. Phase III trial comparing two low dose rates in brachytherapy of cervix carcinoma: report at 2 years. Int J Radiat Oncol Biol Phys. 1993; 25: 405-12.
51. Au SP, Grigsby PW. The irradiation tolerance dose of the proximal vagina. Radiother Oncol. 2003; 67: 77-85.
52. Kirisits C, Lang S, Dimopolous J., et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: design, application, treatment planning, and dosi-metric results. Int J Radiat Oncol Biol Phys. 2006; 65: 624-30.
53. van den Berg AP, van Geel CAJF, van Hooije CMC, et al. Tumor hypoxia - a confounding or exploitable factor in interstitial brachytherapy? Effects of tissue trauma in an experimental rat tumor model. Int J Radiat Oncol Biol Phys. 2000; 48: 233-40.
54. Lindegaard JC, Tanderup K, Nielsen S.K., et al. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2008; 71: 756-64.
55. Wang KL, Yang YC, Chao K.S., et al. Correlation of traditional point a with anatomic location of uterine artery and ureter in cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 2007; 69: 498-503.
56. Yaparpalvi R, Mutyala S, Gorla G.R., et al. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data. Brachytherapy. 2008; 7: 336-42.
57. Kim HJ, Kim S, Ha S.W., et al. Are doses to ICRU reference points valuable for predicting late rectal and bladder morbidity after definitive radiotherapy in uterine cervix cancer? Tumori. 2008; 94: 327-32.
58. Pelloski CE, Palmer M, Chronowski G.M., et al. Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005; 62: 131-7.
59. Haie-Meder C., Potter R, Van Limbergen E, et al. Recommendations from the gynaecological (GYN) GEC ESTRO working group: concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005; 74: 235-45.
60. Paley PJ, Goff BA, Minudri R, et al. The prognostic significance of radiation dose and residual tumor in the treatment of barrel-shaped endophytic cervical carcinoma. Gyn Onc. 2000; 76: 373-9.
61. Eifel PJ, Thoms Jr WW, Smith TL, et al. The relationship between brachytherapy dose and outcome in patients with bulky endocervical tumors treated with radiation alone. Int J Radiat Oncol Biol Phys. 1994; 28: 113-8.
62. Sorbe B, Straumits A, Karlsson L. Intravaginal high-dose-rate brachytherapy for stage I endo-metrial cancer: a randomized study of two dose-per-fraction levels. Int J Radiat Oncol Biol Phys. 2005; 62: 1385-9.
63. Chatani M, Matayoshi Y, Masaki N., et al. A prospective randomized study concerning the point A dose in high dose rate intracavitary therapy for carcinoma of the uterine cervix. The final results. Strahlenther Onkol. 1994; 170: 636-42.
64. Okkan S, Atkovar G, Sahinler I., et al. Results and complications of high dose rate and low dose rate brachytherapy in carcinoma of the cervix: Cerrahpasa experience. Radiother Oncol. 2003; 67: 97-105.
65. Chen SW, Liang JA, Yang S.N., et al. The adverse effect of treatment prolongation in cervical cancer by high dose rate intracavitary brachytherapy. Radiother Oncol. 2003; 67: 69-76.
66. Nag S, Erickson B, Thomadsen B., et al. The American Brachytherapy Society recommendations for high dose rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000; 48: 201-11.
67. Hama Y, Uematsu M, Nagata I., et al. Carcinoma of the uterine cervix: twice versus once-weekly high dose rate brachytherapy. Radiology. 2001; 219: 207-12.
68. Pötter R., Dimopoulos J, Georg P., et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007; 83: 148-55.